LEADER 03802nam 22004813 450 001 9910985626203321 005 20240112080220.0 010 $a9789815136142 010 $a9815136143 035 $a(CKB)29526906900041 035 $a(MiAaPQ)EBC31060391 035 $a(Au-PeEL)EBL31060391 035 $a(Exl-AI)31060391 035 $a(OCoLC)1416923137 035 $a(EXLCZ)9929526906900041 100 $a20240112d2023 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEnzymatic Targets for Drug Discovery Against Alzheimer's Disease 205 $a1st ed. 210 1$aSharjah :$cBentham Science Publishers,$d2023. 210 4$dİ2023. 215 $a1 online resource (289 pages) 311 08$a9789815136159 311 08$a9815136151 327 $aCover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Recent Advances In Tacrine-Based Anti-Alzheimer?s Drug Design -- Atukuri Dorababu1,* -- INTRODUCTION -- Multi-Target Anti-Alzheimer?s Agents -- Tacrine-Heterocycle Hybrids -- Tacrine - Non-Heterocycle Hybrids -- Cholinesterase Inhibitors -- Tacrine-Heterocycle Based ChE Inhibitors -- Tacrine-Non-Heterocycle-Based Derivatives -- DISCUSSION AND CONCLUSION -- REFERENCES -- Epigenetics of Alzheimer?s Disease: Past, Present and Future -- Divya Adiga1, Sangavi Eswaran1, S. Sriharikrishnaa1, Nadeem G. Khan1, Shama Prasada Kabekkodu1,* and Dileep Kumar2,3 -- INTRODUCTION -- Alzheimer?s Disease (AD) -- ROLE OF EPIGENETIC MODIFICATIONS IN AD -- DNA Methylation -- Hydroxy-Methylation -- Mitochondrial DNA Methylation -- Histone Modifications -- Non Coding RNAs (ncRNAs) -- Long-Non Coding RNAs (LncRNAs) in AD Pathogenesis$7Generated by AI. 330 $aThe book summarizes the role of multiple enzyme targets and strategies to design and develop novel drug candidates for Alzheimer's disease (AD). It brings together researchers across the globe having varied scientific backgrounds and expertise in a single volume.The chapters highlight current information scientists have unraveled about the origin, pathogenesis and prevention of AD. The contributions consider both established and emerging drug targets viz. Tau proteins, TREM, and microglia. Topics covered in the book include multi-target anti-Alzheimer's agents, epigenetic modifications, and the role of specific proteins like TMP21 and Tau in AD. A section dedicated to pharmacological treatments discusses the significance of tubulin-modifying enzymes, memantine, and glutamate antagonists. Enzymatic targets for drug discovery are thoroughly examined, focusing on cholinesterase, secretases, and other enzymes. Additionally, the book explores innovative nano-carrier-based drug delivery methods, emphasizing the crucial role of nanotechnology in effective Alzheimer's treatment. The book aims to inform students and researchers in the field of neuroscience, medicine and pharmacology about current research and biochemical nuances of AD pathogenesis and enzymatic drug targeting strategies. Readership Students and researchers in the field of neuroscience, medicine and pharmacology. 606 $aAlzheimer's disease$7Generated by AI 606 $aDrug development$7Generated by AI 615 0$aAlzheimer's disease 615 0$aDrug development 700 $aKumar$b Dileep$01426826 701 $aTiwari$b Prashant$01791882 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910985626203321 996 $aEnzymatic Targets for Drug Discovery Against Alzheimer's Disease$94334814 997 $aUNINA